TABLE 1. Comparison of WHO, NCEP ATP III, and IDF Definitions of the Metabolic Syndrome* Risk factors WHO 3 NCEP ATP III 6,7 IDF 8 DM/IFG or IGT or IR

Size: px
Start display at page:

Download "TABLE 1. Comparison of WHO, NCEP ATP III, and IDF Definitions of the Metabolic Syndrome* Risk factors WHO 3 NCEP ATP III 6,7 IDF 8 DM/IFG or IGT or IR"

Transcription

1 CONCISE REVIEW FOR METABOLIC CLINICIANS SYNDROME The Metabolic Syndrome: Concepts and Controversy LEWIS W. JOHNSON, MD, AND RUTH S. WEINSTOCK, MD, PHD The metabolic syndrome is an insulin-resistant state characterized by a cluster of cardiovascular risk factors, including various combinations of abdominal obesity, glucose intolerance, hypertension, and atherogenic dyslipidemia (elevated triglyceride values, low high-density lipoprotein cholesterol levels, and small dense low-density lipoprotein cholesterol particles). The current epidemic of obesity and physical inactivity has led to an increased prevalence of this disorder. In this review, we discuss the history and pathogenesis of the metabolic syndrome, the controversy regarding the appropriateness of considering it a distinct diagnosis, and the importance of lifestyle modification in its prevention and treatment. The need for all cardiovascular risk factors to be treated, whether or not they are components of the metabolic syndrome, is emphasized. Recent discussions in the literature regarding the continued use of the term metabolic syndrome should be considered a healthy academic debate that hopefully will stimulate ideas and innovative research to improve patient care. Mayo Clin Proc. 2006;81(12): ACE = American College of Endocrinology/American Association of Clinical Endocrinologists; ADA = American Diabetes Association; BMI = body mass index; CVD = cardiovascular disease; DM = diabetes mellitus; EASD = European Association for the Study of Diabetes; FRS = Framingham Risk Score; HDL = high-density lipoprotein; LDL = low-density lipoprotein; NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III; UKPDS = United Kingdom Prospective Diabetes Study; WC = waist circumference; WHO = World Health Organization The metabolic syndrome describes a group of modifiable risk factors occurring in the same individual and associated with an increased risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus (DM). Reports of clustering of metabolic risk factors are not new and date back to the early 1920s. 1 However, there was little interest in this phenomenon until 1988, when Reaven 2 coined the term syndrome X to describe a disorder consisting of insulin resistance, glucose intolerance, increased triglyceride and decreased high-density lipoprotein (HDL) cholesterol levels, and hypertension. He postulated that the common feature was insulin resistance and that all the other changes were likely to be secondary to this basic abnormality. Additionally, he noted that the more obese and sedentary an individual, the greater the degree of insulin resistance. From the Division of Endocrinology, Diabetes and Metabolism, SUNY Upstate Medical University, Syracuse, NY (L.W.J., R.S.W.) and Veterans Affairs Medical Center, Syracuse, NY (R.S.W.). A question-and-answer section appears at the end of this article. Address reprint requests and correspondence to Ruth S. Weinstock, MD, PhD, Division of Endocrinology, Diabetes and Metabolism, SUNY Upstate Medical University, 750 E Adams St, CWB 353, Syracuse, NY ( weinstor@upstate.edu) Mayo Foundation for Medical Education and Research DEFINITIONS The World Health Organization (WHO) first defined the syndrome in and called it the metabolic syndrome, a term that had been used by Zimmet 4 in 1991 to describe this cluster of findings. The WHO criteria for the metabolic syndrome required the presence of diabetes mellitus (DM), impaired fasting glucose, impaired glucose tolerance, or insulin resistance (assessed by the euglycemic insulin clamp technique) plus 2 additional factors. In 1999, the European Group for the Study of Insulin Resistance 5 suggested that a more appropriate term would be the insulin resistance syndrome and modified the criteria to require fasting hyperinsulinemia plus 2 other factors using different cutpoints than those used by the WHO. One of the criteria was an increased waist circumference (WC) to reflect abdominal obesity. In 2001, the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) 6 simplified the definition to make it user-friendly for practitioners (Table 1). The NCEP ATP III required any 3 of 5 risk factors: abnormal WC, high triglyceride level, low HDL cholesterol level, high blood pressure, and high fasting plasma glucose concentration (Table 1). The NCEP ATP III criteria were updated in 2005 to correspond with the new American Diabetes Association (ADA) standard of a normal fasting glucose level of less than 100 mg/dl. 7 In 2003, the American College of Endocrinology/American Association of Clinical Endocrinologists (ACE) published a position statement 9 recommending that the appropriate term should be the insulin resistance syndrome and stressing that it places the individual at increased risk for not only type 2 DM and CVD but also other disease states associated with insulin resistance (essential hypertension, polycystic ovary syndrome, nonalcoholic fatty liver disease, certain forms of cancer, and sleep apnea). The ACE statement was meant to be more an explanation of the mechanisms of the syndrome, rather than another competing definition. The latest criteria were proposed by the International Diabetes Federation 8 and are similar to the more commonly used NCEP ATP III definition but require measurement of abdominal girth, which has different cutoff values based on ethnicity and is seldom completed in a busy office setting. The WHO, NCEP ATP III, and International Diabetes Federation criteria for metabolic syndrome are summarized in Table 1, and ethnicity-specific WC cut points are shown in Table 2. The rationale for using different WC values is that Asians have a Mayo Clin Proc. December 2006;81(12):

2 TABLE 1. Comparison of WHO, NCEP ATP III, and IDF Definitions of the Metabolic Syndrome* Risk factors WHO 3 NCEP ATP III 6,7 IDF 8 DM/IFG or IGT or IR plus Any 3 risk factors Increased WC (ethnicity-specific) plus any 2 any 2 risk factors risk factors Obesity Waist-to-hip ratio >0.90 in WC 102 cm (40 in) in men or 88 cm (35 in) WC criteria dependent on ethnicity men and >0.85 in women in women and/or BMI >30 kg/m 2 Triglycerides 150 mg/dl 150 mg/dl or drug treatment for elevated 150 mg/dl or drug treatment for elevated levels levels HDL cholesterol <35 mg/dl in men and <40 mg/dl in men and <50 mg/dl in women <40 mg/dl in men and <50 mg/dl in women <39 mg/dl in women or drug treatment for reduced levels or drug treatment for reduced levels Blood pressure 140/90 mm Hg 130 mm Hg systolic or 85 mm Hg diastolic 130 mm Hg systolic or 85 mm Hg diastolic or drug treatment for hypertension or drug treatment for hypertension Fasting plasma glucose IGT, IFG, or type 2 DM 100 mg/dl or drug treatment for DM 100 mg/dl or drug treatment for DM Microalbuminuria >30 mg albumin/g creatinine *Criteria for the diagnosis of diabetes mellitus (DM) (each must be confirmed on a subsequent day): symptoms of DM plus casual plasma glucose level >199 mg/dl or fasting plasma glucose level >125 mg/dl or 2-hour plasma glucose level after 75-g glucose load >199 mg/dl. BMI = body mass index; IDF = International Diabetes Federation; IFG = impaired fasting glucose (fasting plasma glucose level, mg/dl); IGT = impaired glucose tolerance (2-hour plasma glucose level after 75-g glucose load, mg/dl); IR = insulin resistance; NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III; WC = waist circumference; WHO = World Health Organization. higher incidence of insulin resistance and DM at a lower body mass index (BMI) (calculated as weight in kilograms divided by the square of height in meters) and WC than Europeans. 10 All 3 versions allow the inclusion of patients with DM and share the common goal of identifying individuals at increased risk for developing CVD. Of note, the presence of DM is generally considered a CVD risk equivalent. 6,11 CLINICAL IMPORTANCE The pandemic of obesity, metabolic syndrome, and diabetes has sparked a tremendous interest in the medical literature. A MEDLINE search limited to English-language articles with the terms metabolic syndrome, insulin resistance syndrome, or syndrome X in the title returned 4024 articles published during the past 5 years, 1408 of which were published in the 12 months ending in March TABLE 2. Ethnicity-Specific Values for Waist Circumference Ethnic group Waist circumference (cm) US American 6 Men: 102 Women: 88 European Men: 94 Women: 80 South Asian Men: 90 Women: 80 Chinese Men: 90 Women: 80 Japanese Men: 90 Women: 80 Native South and Use South Asian recommendations Central American until more specific data are available Sub-Saharan African Use European data until more specific data are available Eastern Mediterranean and Use European data until more specific Middle Eastern (Arab) data are available Adapted from Lancet, 8 with permission. Using measured heights and weights, results from the National Health and Nutrition Examination Survey indicate that in US adults aged 20 to 74 years, the age-adjusted prevalence of being either overweight or obese (BMI, 25 kg/m 2 ) increased from 47% in to 65% in During the same period, obesity (BMI, 30 kg/m 2 ) doubled from 15% to 31%. 12 Overweight and obesity are independent risk factors for CVD, the leading cause of death and disability in US adults. The prevalence of CVD in people 25 years or older who have normal weight (BMI, kg/m 2 ) or are overweight (BMI, kg/m 2 ) or obese (BMI, 30 kg/m 2 ) is 20%, 28%, and 39%, respectively. 13 In association with increasing obesity, the ageadjusted prevalence of the metabolic syndrome in the US population aged 25 years or older has increased from 24% in to 27% in , and in those older than 60 years, the prevalence is more than 40%. 14 Depending on the definition used and the population studied, the risk of an individual with the metabolic syndrome developing type 2 DM or CVD has varied. In a recent review by Grundy, 15 the risk of type 2 DM developing was estimated to be 5 times greater in persons with the metabolic syndrome without DM than in those not meeting 3 of the 5 NCEP ATP III criteria, and the relative risk of CVD was doubled. Obesity and metabolic syndrome have also been increasing at an alarming rate in children and adolescents. 16 An estimated 1 million US adolescents meet the criteria for the metabolic syndrome. 17 In the Bogalusa Heart Study, 18 autopsies of young people who had died of trauma showed that the extent of atherosclerosis in the aorta and coronary arteries correlated with the number of metabolic risk factors Mayo Clin Proc. December 2006;81(12):

3 Overweight/obesity and a sedentary lifestyle are becoming the norm in the United States, and physicians are seeing increasing numbers of persons with this cluster of factors. This group of risk factors, as well as the individual risk factors, place patients at increased risk of developing type 2 DM and CVD and contribute to the development of other potentially devastating conditions such as infertility, malignancy, steatohepatitis, and degenerative arthritis. On the basis of these trends, concern that a subsequent major increase in CVD will occur over the next 2 decades is reasonable. PATHOGENESIS The prevailing theory is that in most people with the metabolic syndrome, the development of obesity and physical inactivity leads to insulin resistance and compensatory hyperinsulinemia. Most insulin-resistant individuals are able to maintain the degree of hyperinsulinemia required to prevent decompensation of glucose homeostasis. If pancreatic insulin secretion fails to increase adequately, impaired glucose tolerance or DM develops. Genetic factors probably play a role in the varied clinical manifestations seen in individual patients. The metabolic syndrome is a proinflammatory and prothrombotic state, with glucotoxicity and lipotoxicity contributing to the metabolic and vascular abnormalities. Adipose tissue not only stores fat but also is an active endocrine organ with receptors that respond to signals from many sources, including the central nervous system. Adipose tissue is a source of metabolically active substances including elevated levels of free fatty acids, which affect parallel insulin-signaling pathways in the liver, skeletal muscle, and blood vessels, leading to hyperglycemia and endothelial dysfunction. Abnormalities include increased gluconeogenesis, decreased glucose uptake in skeletal muscle, loss of vasodilation, platelet aggregation, increased oxidative stress, and the formation of advanced glycation end products. Insulin resistance also affects the production of inflammatory cytokines (tumor necrosis factor α, interleukin 6), prothrombotic substances (fibrinogen, plasminogen activator inhibitor 1), and other molecules such as resistin, adiponectin (anti-inflammatory), and leptin. Persons with the metabolic syndrome tend to have central or abdominal obesity in contrast to lower-body obesity. Central obesity is associated with a greater amount of visceral fat than is lower-body obesity, which is associated with more subcutaneous fat. Visceral fat is metabolically active, producing free fatty acids and inflammatory cytokines that drain directly into the liver via the portal circulation. Fat deposits in the liver are associated with overproduction of very-low-density lipoprotein, predisposing the patient to atherogenic dyslipidemia (elevated triglycerides, low HDL cholesterol levels, and small dense low-density lipoprotein [LDL] cholesterol particles). Although LDL cholesterol levels may not be elevated, the number of particles may be increased, and the small dense particles more readily enter the arterial wall and are oxidized, leading to atherosclerosis. In addition to impaired glucose tolerance and atherogenic dyslipidemia, the insulin-resistant state, in at least some individuals, promotes development of hypertension. Endothelial dysfunction causes vascular changes and affects blood flow. Even with no detectable abnormality in glucose metabolism, other manifestations of insulin resistance can be present, including increased production of inflammatory cytokines. It is now well known that inflammation and oxidation play key roles in the etiology and progression of CVD. 19 Factors responsible for the initiation of the insulinresistant state and the basis for individual variation in its manifestations are being actively investigated. RECENT CONTROVERSY The ADA and the European Association for the Study of Diabetes (EASD) recently published a joint statement questioning the clinical value of the metabolic syndrome. 20 Their concerns were as follows: (1) the criteria for the diagnosis of metabolic syndrome are ambiguous, and the rationale for thresholds is ill defined; (2) the value of including DM in the definition of metabolic syndrome is questionable; (3) the validity of using insulin resistance as the unifying etiology is uncertain; (4) there is no clear basis for including/excluding other CVD risk factors; (5) the CVD risk value varies and depends on the specific risk factors present; (6) the CVD risk associated with the syndrome appears to be no greater than the sum of its parts; (7) treatment of the syndrome is no different than the treatment of its components; and (8) the medical value of diagnosing the syndrome is unclear. The authors of the ADA/EASD joint statement suggest a research agenda to critically analyze how the syndrome is defined and to determine its usefulness in predicting CVD risk over and above that of the individual components. The ADA/EASD statement resulted in the publication of articles in the lay press, including USA TODAY, 21 The New York Times, and The Washington Post. The National Heart, Lung, and Blood Institute and the American Heart Association 7 continue to support the use of the term metabolic syndrome to describe an entity that increases the risk of developing CVD and type 2 DM and its use as a secondary target for reducing CVD events after the primary targets of smoking cessation, lowering LDL cholesterol levels, and blood pressure control. They agree that further Mayo Clin Proc. December 2006;81(12):

4 research is needed to refine the most appropriate therapies for patients with the metabolic syndrome. In a recent statement, 22 the ACE restated their original opinion 8 that the term insulin resistance syndrome more clearly describes the pathophysiology of this syndrome and that it is a major driver of atherosclerosis and DM and may play a role in disorders as diverse as infertility, malignancy, and abnormalities of liver function (fatty liver). The ACE specifically distinguished insulin resistance syndrome from type 2 DM and CVD because one of the most important goals was to identify individuals at risk before such consequences occurred. They believe it has been helpful to recognize the clustering of factors that increase the risk of an individual being insulin resistant as a syndrome. Furthermore, they assert that the concept is clinically useful and has led physicians to search for related risk factors and associated illnesses. Several recognized authorities have also voiced their opinions regarding the clinical utility of the continued use of the concept of the metabolic syndrome In July 2006, a joint statement from the ADA and the American Heart Association regarding this recent controversy was published simultaneously in Diabetes Care 26 and Circulation. 27 The associations stated that they remain committed to CVD risk factor recognition and treatment. The ADA prefers assessing and treating cardiometabolic risk. The joint statement stresses the importance of lifestyle modification, including weight loss and increased physical activity. Questioning of the concept of the metabolic syndrome is not new. In the 1998 report, 3 the WHO noted that persons with central obesity, hypertension, and dyslipidemia, with or without hyperglycemia, present a major classification, diagnostic, and therapeutic challenge. They called for a clear description of the essential components of the syndrome and data to support the relative importance of each component. They also noted that internationally acknowledged criteria for central obesity, insulin resistance, and hyperinsulinemia would be of assistance. Unfortunately, 8 years later, we have not satisfactorily answered these questions. DISCUSSION The NCEP ATP III criteria have definite flaws. First, the 5 criteria and the cutoffs appear to be arbitrary and not evidence based. Second, the risk factor values are continuous and must be considered as such, not just as present or absent. The fact that CVD risk increases with increasing blood glucose levels, systolic blood pressure, and LDL cholesterol values has been well documented. Third, important risk factors such as LDL cholesterol, cigarette smoking, family history, and age are not included, limiting the usefulness of the metabolic syndrome in predicting CVD risk. Finally, the inclusion of individuals with the diagnosis of DM is confusing because the metabolic syndrome is considered useful in predicting CVD risk, but DM alone is considered a CVD equivalent that requires aggressive treatment. The metabolic syndrome has been defined in several ways and thus cannot be considered a precise diagnosis. Rather, its presence should alert health care professionals to assess for all CVD risk factors and serve as a reminder that an individual is at increased risk of developing DM or CVD. The diagnosis of metabolic syndrome is an indicator of long-term cardiovascular risk, but for short-term risk assessment, the Framingham Risk Score (FRS) 28 is superior. The NCEP ATP III modification of the FRS includes age, sex, total cholesterol, LDL cholesterol, HDL cholesterol, systolic blood pressure, family history of early coronary heart disease, and smoking status and provides the 10-year risk of having a coronary event. The calculator can be downloaded to a desktop or handheld computer, and a table for manual calculation is also available ( For patients with type 2 DM, the FRS is inaccurate, and the United Kingdom Prospective Diabetes Study (UKPDS) risk engine 29 can be used. The UKPDS risk engine provides risk estimates and 95% confidence intervals in individuals with type 2 DM for nonfatal and fatal coronary heart disease and stroke. In addition to age, sex, ethnicity, total cholesterol, HDL cholesterol, systolic blood pressure, and smoking status, the UKPDS risk engine includes duration of DM and hemoglobin A 1c. This calculator can be downloaded to a desktop or handheld computer ( A new pen-and-paper 10-year risk estimator for type 2 DM based on the UKPDS risk engine has been developed for use in situations in which a computer is not readily available. 30 Because age is heavily weighted in both the FRS and the UKPDS risk evaluators, the 10-year risk of developing CVD may be calculated to be relatively low in younger individuals, yet they are at high long-term risk. Recently, the ADA made available the Diabetes PHD (Personal Health Decisions) cardiometabolic risk calculator that is based on the Archimedes model (Archimedes Inc, San Francisco, Calif) and incorporates age, race/ethnicity, sex, weight, family history, smoking, physical activity, and medications in addition to fasting blood sugar (hemoglobin A 1c if diabetic), serum lipids, and blood pressure to estimate the risk of developing diabetes and CVD. This calculator can be accessed by both health care professionals and patients at In patients with impaired glucose tolerance, both the Diabetes Prevention Program 31 and the Finnish Diabetes Prevention Study 32 behavior modification interventions produced identical 58% reductions in progression to type 2 DM. A secondary analysis of the Diabetes Prevention Pro Mayo Clin Proc. December 2006;81(12):

5 gram showed that over 3.2 years, the prevalence of the metabolic syndrome decreased from 51% to 43% in the lifestyle intervention group and increased from 55% to 61% in the conventional care group, demonstrating that lifestyle modification is effective in delaying or preventing the development of both the metabolic syndrome and DM. 33 A diet that produces a 7% to 10% weight loss combined with moderate exercise such as walking for 30 minutes on most days of the week is effective, and this message should be conveyed to patients. Weight-loss drugs and bariatric surgery can be used in appropriate, carefully selected patients, but discussion of these therapies is beyond the scope of this review. Lifestyle modification, including weight loss, healthy diet, and increased physical activity, is the cornerstone of therapy for the metabolic syndrome as well as for its component risk factors. Almost all energy-restricted diets result in short-term weight loss, but the challenge is long-term weight maintenance. Including an exercise regimen in daily life appears to play a major beneficial role. Pharmacological therapy should be used to attain glycemic, blood pressure, and lipid goals. Guidelines for the management of hyperglycemia, hypertension, and dyslipidemia are available. 6,34,35 Smoking assessment and the need for prophylactic aspirin are also important. Updated guidelines (2006) for the secondary prevention of CVD recommend aggressive treatment of all risk factors, emphasizing blood pressure and LDL cholesterol reduction, lifestyle change, and glycemic control. 36 CONCLUSION Whether the constellation of vascular risk factors is called metabolic syndrome, insulin resistance syndrome, syndrome X, increased cardiometabolic risk, or another name is of limited clinical importance. The fact is that physicians are seeing increasing numbers of persons, including children, with obesity and varying combinations of glucose intolerance or DM, hypertension, and dyslipidemia. Simple solutions for the public health issue of obesity and lack of exercise are not available and will require the cooperation of local, state, and federal government agencies, corporate entities, and many disciplines of medicine. The public must be made aware that the relationship of obesity to DM and heart disease is analogous to that of smoking and lung cancer. Patients with DM or established CVD require aggressive management, and adding a diagnosis of metabolic syndrome adds little value to their care. Any risk factor requires attention, including lifestyle change and/or medications. Aggressive treatment of all major CVD risk factors, including the components of the metabolic syndrome, is critical for the health of the world s population. REFERENCES 1. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens. 2006;24: Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37: Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998; 15: Zimmet PZ. Kelly West Lecture 1991: challenges in diabetes epidemiology from West to the rest. Diabetes Care. 1992;15: Balkau B, Charles MA, European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report of the WHO consultation [letter]. Diabet Med. 1999;16: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published corrections appear in Circulation. 2005;112:e297, e298]. Circulation. 2005;112: Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet. 2005;366: Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9: Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27: Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: National Center for Health Statistics. Prevalence of Overweight and Obesity Among Adults: United States, Available at: /products/pubs/pubd/hestats/obese/obse99.htm. Accessed October 26, Wang G, Zheng ZJ, Heath G, Macera C, Pratt M, Buchner D. Economic burden of cardiovascular disease associated with excess body weight in U.S. adults. Am J Prev Med. 2002;23: Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27: Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol Mar 21;47: Epub 2006 Feb Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350: Daniels SR, Arnett DK, Eckel RH, et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation. 2005;111: Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA, Bogalusa Heart Study. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338: Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352: Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28: Sternberg S. Metabolic syndrome doesn t exist, diabetes groups claim. USA TODAY. August 25, Available at: / metabolicsyndrome_x.htm. Accessed October 27, Mechanick JI, Cobin RH, Einhorn D, Handelsman Y, Hellman R, Jellinger PS. American College of Endocrinology/American Association of Clinical Endocrinologists: reaffirmation of the 2003 ACE Insulin Resistance Syndrome (IRS) Position Statement. Available at: /guidelines/irsstatement.pdf. Accessed October 27, Gotto AM Jr, Blackburn GL, Dailey GE III, et al. The metabolic syndrome: a call to action. Coron Artery Dis. 2006;17: Mayo Clin Proc. December 2006;81(12):

6 24. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365: Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem Jun;51: Epub 2005 Mar Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care. 2006;29: Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006;113: Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165: Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56) [published correction appears in Clin Sci (Lond). 2002;102:679]. Clin Sci (Lond). 2001;101: Christianson TJH, Bryant SC, Weymiller AJ, Smith SA, Montori VM. A pen-and-paper coronary risk estimator for office use with patients with type 2 diabetes. Mayo Clin Proc. 2006;81: Knowler WC, Barrett-Connor E, Fowler SE, et al, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346: Tuomilehto J, Lindstrom J, Eriksson JG, et al, Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344: Orchard TJ, Temprosa M, Goldberg R, et al, Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142: Chobanian AV, Bakris GL, Black HR, et al, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report [published correction appears in JAMA. 2003;290:197]. JAMA May 21;289: Epub 2003 May American Diabetes Association. Standards of medical care in diabetes 2006 [published correction appears in Diabetes Care. 2006;29:1192]. Diabetes Care. 2006;29(suppl 1):S4-S Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update [published correction appears in Circulation. 2006;113:e847]. Circulation. 2006;113: Questions About Metabolic Syndrome 1. Which one of the following is the correct current estimated prevalence of obesity (BMI, 30 kg/m 2 ) in US adults aged 20 to 74 years? a. 10% b. 20% c. 31% d. 65% e. 90% 2. Which one of the following is not a NCEP ATP III criterion for diagnosis of the metabolic syndrome? a. Increased WC b. Blood pressure 130/85 mm Hg c. Elevated uric acid d. Triglycerides 150 mg/dl e. Fasting plasma glucose 100 mg/dl 3. The lipid pattern observed in individuals with the metabolic syndrome is characterized by which one of the following? a. High triglyceride and low HDL cholesterol levels and small dense LDL cholesterol particles b. High total cholesterol and LDL cholesterol levels c. High triglyceride and normal HDL cholesterol levels d. High triglyceride and LDL cholesterol levels e. Low triglyceride, normal HDL cholesterol, and high LDL cholesterol levels 4. Which one of the following statements about the metabolic syndrome is false? a. It is an excellent predictor of 10-year risk of a coronary event b. It is associated with an increased long-term risk of CVD and type 2 DM c. It occurs in about 27% of the US population d. Its incidence increases with increasing age e. Its incidence is increasing in children 5. Which one of the following is not associated with insulin resistance? a. Nonalcoholic fatty liver disease b. Some cancers c. Polycystic ovary syndrome d. Type 2 DM e. Hyperthyroidism Correct answers: 1. c, 2. c, 3. a, 4. a, 5. e 1620 Mayo Clin Proc. December 2006;81(12):

Metabolic Syndrome: What s in a name?

Metabolic Syndrome: What s in a name? Commentary Metabolic Syndrome: What s in a name? Deborah P. Wubben, MD, MPH; Alexandra K. Adams, MD, PhD Abstract The term metabolic syndrome has recently become en vogue. But is the definition realistic,

More information

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health

More information

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic

More information

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine

More information

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:

More information

Metabolic Syndrome: Why Should We Look For It?

Metabolic Syndrome: Why Should We Look For It? 021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you

More information

Welcome and Introduction

Welcome and Introduction Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

The American Diabetes Association estimates

The American Diabetes Association estimates DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular

More information

DOI: /01.CIR C6

DOI: /01.CIR C6 Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition Scott M. Grundy, H. Bryan Brewer,

More information

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for

More information

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H. U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,

More information

Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya

Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya Original Article Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study Alshkri MM 1, Elmehdawi RR 2 1 Benghazi Diabetes Center. 2 Medical Department, Faculty of Medicine,

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Metabolic Syndrome.

Metabolic Syndrome. www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present

More information

Diabetic Dyslipidemia

Diabetic Dyslipidemia Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents

More information

Obesity, Metabolic Syndrome, and Diabetes: Making the Connections

Obesity, Metabolic Syndrome, and Diabetes: Making the Connections Obesity, Metabolic Syndrome, and Diabetes: Making the Connections Alka M. Kanaya, M.D. Associate Professor of Medicine & Epi/Biostats University of California, San Francisco February 26, 21 Roadmap 1.

More information

Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance

Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance CLINICAL PRACTICE Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance John MF. Adam*, Daniel Josten** ABSTRACT The American Diabetes Association has strongly recommended that fasting

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

Established Risk Factors for Coronary Heart Disease (CHD)

Established Risk Factors for Coronary Heart Disease (CHD) Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland

More information

8/15/2018. Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome. Metabolic Syndrome.

8/15/2018. Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome. Metabolic Syndrome. Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome Diagnostic Criteria (3/5) Metabolic Syndrome Key Facts JAN BRIONES DNP, APRN, CNP FAMILY NURSE PRACTITIONER Abdominal

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Rehabilitation and Research Training Center on Secondary Conditions in Individuals with SCI. James S. Krause, PhD

Rehabilitation and Research Training Center on Secondary Conditions in Individuals with SCI. James S. Krause, PhD Disclosure The contents of this presentation were developed with support from educational grants from the Department of Education, NIDRR grant numbers H133B090005, H133B970011 and H133G010160. However,

More information

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043

More information

The metabolic syndrome has received increased attention

The metabolic syndrome has received increased attention AHA/NHLBI Scientific Statement Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Scott M. Grundy, MD, PhD,

More information

The IDF consensus worldwide definition of the metabolic syndrome

The IDF consensus worldwide definition of the metabolic syndrome International Diabetes Federation Avenue Emile De Mot 19 B-1000 Brussels, Belgium Telephone +32-2-5385511 Telefax +32-2-5385114 info@idf.org www.idf.org VAT BE433.674.528 The IDF consensus worldwide definition

More information

METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS

METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS Rev. Med. Chir. Soc. Med. Nat., Iaşi 2012 vol. 116, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS Ana-Maria Pelin 1, Silvia Mǎtǎsaru 2 University

More information

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still

More information

DIABETES. A growing problem

DIABETES. A growing problem DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought

More information

Chapter 2 The Metabolic Syndrome

Chapter 2 The Metabolic Syndrome Chapter 2 The Metabolic Syndrome Matthew J. Sorrentino Keywords Waist circumference Abdominal obesity Impaired fasting glucose HDL-cholesterol Triglycerides Metabolic syndrome is the designation given

More information

5/28/2010. Pre Test Question

5/28/2010. Pre Test Question Myth of Metabolic Syndrome? C. W. Spellman, DO, PhD Professor and Associate Dean Research Dir. Center Diabetes and Metabolic Disorders Department Internal Medicine, Div. Endocrinology Texas Tech University

More information

On May 2001, the Third Adult

On May 2001, the Third Adult THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011 Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled

More information

METABOLIC SYNDROME IN REPRODUCTIVE FEMALES

METABOLIC SYNDROME IN REPRODUCTIVE FEMALES METABOLIC SYNDROME IN REPRODUCTIVE FEMALES John J. Orris, D.O., M.B.A Division Head, Reproductive Endocrinology & Infertility, Main Line Health System Associate Professor, Drexel University College of

More information

Nutrition in Metabolic Syndrome Topic 24

Nutrition in Metabolic Syndrome Topic 24 Nutrition in Metabolic Syndrome Topic 24 Module 24.1 Diagnostic criteria for Metabolic Syndrome Learning Objectives: María Cristina Cuerda Compés Study the diagnostic criteria for Metabolic Syndrome; Define

More information

Although medical advances have curbed

Although medical advances have curbed PREVENTION OF CORONARY HEART DISEASE IN THE METABOLIC SYNDROME AND DIABETES MELLITUS * Sherita Hill Golden, MD, MHS ABSTRACT The leading cause of death in patients with diabetes is cardiovascular disease.

More information

JMSCR Volume 03 Issue 04 Page April 2015

JMSCR Volume 03 Issue 04 Page April 2015 www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Study of Metabolic Syndrome and Thyroid Dysfunction Authors Dr. Nalini R Humaney, Dr. Saurabh Ashok Lande, Dr. Ramesh P Mundle N.K.P.Salve

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

Metabolic Syndrome : Myth Of Reality. PD Khandelwal EVOLUTION OF METABOLIC SYNDROME

Metabolic Syndrome : Myth Of Reality. PD Khandelwal EVOLUTION OF METABOLIC SYNDROME Metabolic Syndrome : Myth Of Reality PD Khandelwal EVOLUTION OF METABOLIC SYNDROME After being given a series of names throughout the path of its evolution since 1922,when a Swedish physician named kylin

More information

Roadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total

Roadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total Diabetes and the Metabolic Syndrome in the Asian Population Alka Kanaya, MD Associate Professor of Medicine, UCSF Feb 26, 2010 Roadmap 1. Diabetes in Asian Americans Prevalence in the U.S. Risk factors

More information

Contents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies

Contents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies Contents I. CV disease and insulin resistance: Challenges and opportunities II. Insulin sensitizers: Surrogate and clinical outcomes studies IV. Identifying and treating patients with insulin resistance

More information

Joslin Diabetes Center Primary Care Congress for Cardiometabolic Health 2013 The Metabolic Syndrome: Is It a Valid Concept?

Joslin Diabetes Center Primary Care Congress for Cardiometabolic Health 2013 The Metabolic Syndrome: Is It a Valid Concept? The Metabolic Syndrome: A Defeated Emperor What were (are) the problems? Well 1. There was no agreed upon pathogenic reason to identify people with the metabolic syndrome 2. It was a relatively poor way

More information

How to Reduce CVD Complications in Diabetes?

How to Reduce CVD Complications in Diabetes? How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year

More information

METABOLIC SYNDROME IN TYPE-2 DIABETES MELLITUS

METABOLIC SYNDROME IN TYPE-2 DIABETES MELLITUS METABOLIC SYNDROME IN TYPE-2 DIABETES MELLITUS S.M. Sohail Ashraf 1, Faisal Ziauddin 2, Umar Jahangeer 3 ABSTRACT Objective: To find out the prevalence of metabolic syndrome in type-2 Diabetes Mellitus

More information

Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis

Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser

More information

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of

More information

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes

More information

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1

More information

Metabolic Syndrome in Asians

Metabolic Syndrome in Asians Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly

More information

Fasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes: The Cooper Center Longitudinal Study

Fasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes: The Cooper Center Longitudinal Study Fasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes: The Cooper Center Longitudinal Study Laura F. DeFina, MD,* Gloria Lena Vega, PhD,Þ David Leonard, PhD,Þ and Scott M. Grundy,

More information

Metabolic syndrome. Metabolic syndrome and prediabetes appear to be the same disorder, just diagnosed by a different set of biomarkers.

Metabolic syndrome. Metabolic syndrome and prediabetes appear to be the same disorder, just diagnosed by a different set of biomarkers. Metabolic syndrome Metabolic syndrome is a disorder of energy utilization and storage, diagnosed by a co-occurrence of three out of five of the following medical conditions: abdominal (central) obesity,

More information

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the

More information

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD ) 005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,

More information

RECENTLY, A DEBATE has emerged whether the concept

RECENTLY, A DEBATE has emerged whether the concept 0021-972X/07/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 92(2):399 404 Printed in U.S.A. Copyright 2007 by The Endocrine Society doi: 10.1210/jc.2006-0513 CONTROVERSY IN CLINICAL ENDOCRINOLOGY

More information

Effective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.

Effective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D. Effective Interventions in the Clinical Setting: Engaging and Empowering Patients Michael J. Bloch, M.D. Doina Kulick, M.D. UNIVERSITY OF NEVADA SCHOOL of MEDICINE Sept. 8, 2011 Reality check: What could

More information

Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study

Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study (28) 32, S11 S16 & 28 Nature Publishing Group All rights reserved 37-6/8 $3. www.nature.com/ijo ORIGINAL ARTICLE Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular

More information

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global

More information

Available from Deakin Research Online: Copyright : 2009, Elsevier Ireland Ltd

Available from Deakin Research Online:   Copyright : 2009, Elsevier Ireland Ltd Deakin Research Online Deakin University s institutional research repository DDeakin Research Online Research Online This is the authors final peer reviewed version of the item published as: Cameron, Adrian

More information

Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions

Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes is one of the largest global health emergencies of 21 st century, with the number of people with

More information

Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico

Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico Presented in Collaboration with New Mexico Health Care Takes On Diabetes Discuss the burden and challenges prediabetes presents in New Mexico.

More information

Risks and benefits of weight loss: challenges to obesity research

Risks and benefits of weight loss: challenges to obesity research European Heart Journal Supplements (2005) 7 (Supplement L), L27 L31 doi:10.1093/eurheartj/sui083 Risks and benefits of weight loss: challenges to obesity research Donna Ryan* Pennington Biomedical Research

More information

PREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS

PREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS PREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS Mehmet Emre Atabek,MD,PhD Necmettin Erbakan University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology and

More information

Discussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting

Discussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be

More information

HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME

HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME What does the term Metabolic Syndrome describe? Metabolic syndrome describes a cluster of cardio-metabolic conditions that increase one's risk of developing

More information

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes

Accelerated atherosclerosis begins years prior to the diagnosis of diabetes Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients

More information

EVA, Metabolic Syndrome and rehabilitation

EVA, Metabolic Syndrome and rehabilitation Baltic Rehab Congress Tallinn 17th September 2010 EVA, Metabolic Syndrome and rehabilitation Peter Nilsson, MD, PhD Department of Clinical Sciences Lund University University Hospital, Malmo, Sweden Metabolic

More information

Atherosclerotic Disease Risk Score

Atherosclerotic Disease Risk Score Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,

More information

Metabolic syndrome and insulin resistance in an urban and rural adult population in Sri Lanka

Metabolic syndrome and insulin resistance in an urban and rural adult population in Sri Lanka Original Metabolic paper syndrome and insulin resistance in an urban and rural adult population in Sri Lanka Metabolic syndrome and insulin resistance in an urban and rural adult population in Sri Lanka

More information

MANAGING THE PRE-DIABETIC PATIENT

MANAGING THE PRE-DIABETIC PATIENT Managing the PreDiabetic Patient CAPA 2012 2 Key Questions MANAGING THE PRE-DIABETIC PATIENT Ingrid Lopes, DO 1. What is pre-diabetes and is it a disease? 2. What is the metabolic key? 3. When and how

More information

Goals of today s talk. How to Stop Prediabetes from Becoming Diabetes. Goals of today s talk. Type 2 diabetes mellitus

Goals of today s talk. How to Stop Prediabetes from Becoming Diabetes. Goals of today s talk. Type 2 diabetes mellitus Goals of today s talk How to Stop Prediabetes from Becoming Diabetes Zara Frankel, MD Boulder Creek Family Medicine 303-720-6956 Diabetes is a devastating disease Prediabetes and diabetes are on different

More information

PREDIABETES TESTING SERVICES

PREDIABETES TESTING SERVICES PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at

More information

... REPORT... The Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease: Understanding the Role of Insulin Resistance

... REPORT... The Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease: Understanding the Role of Insulin Resistance ... REPORT... The Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease: Understanding the Role of Insulin Resistance David M. Kendall, MD; Anne Peters Harmel, MD Abstract The most common and

More information

Statistical Fact Sheet Populations

Statistical Fact Sheet Populations Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total

More information

The Metabolic Syndrome Prof. Jean-Pierre Després

The Metabolic Syndrome Prof. Jean-Pierre Després The Metabolic Syndrome 1 Jean-Pierre Després, Ph.D., FAHA, FIAS Quebec Heart and Lung Institute Department of Medicine Université Laval Québec, Canada Reaven s syndrome X Triglycerides HDL cholesterol

More information

Impact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients

Impact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients 2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Seminar. The metabolic syndrome

Seminar. The metabolic syndrome The metabolic syndrome Robert H Eckel, Scott M Grundy, Paul Z Zimmet The metabolic syndrome is a common metabolic disorder that results from the increasing prevalence of obesity. The disorder is defined

More information

Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010

Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010 Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010 CAVEAT LECTOR 2 CVD-related Mortality in Aging SCI GU

More information

Risk Factors for Heart Disease

Risk Factors for Heart Disease Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress

More information

Cardiometabolic Side Effects of Risperidone in Children with Autism

Cardiometabolic Side Effects of Risperidone in Children with Autism Cardiometabolic Side Effects of Risperidone in Children with Autism Susan J. Boorin, MSN, PMHNP-BC PhD Candidate Yale School of Nursing 1 This speaker has no conflicts of interest to disclose. 2 Boorin

More information

Asubstantial minority of adults and adolescents

Asubstantial minority of adults and adolescents THE METABOLIC SYNDROME AS A RISK FACTOR FOR TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE Roger S. Blumenthal, MD* ABSTRACT This paper discusses the prevalence and clinical significance of the metabolic syndrome

More information

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple

More information

Metabolic syn and CVD. Dr : dehestani Imam reza hospital

Metabolic syn and CVD. Dr : dehestani Imam reza hospital Metabolic syn and CVD { Dr : dehestani Imam reza hospital Global Distribution of CVDs as Causes of Death, WHO 2011 Worldwide Mortality from Ischemic Heart Disease and Cerebrovascular Disease 2011 Ischemic

More information

Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese

Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,

More information

Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes

Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes ...PRESENTATIONS... Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Based on a presentation by Ronald B. Goldberg, MD Presentation Summary Atherosclerosis accounts for approximately

More information

BDS, MSc, MSPH, MHPE, FFPH, ScD. Associate Prof. of Epidemiology and Biostatistics. Associate Prof. Medical Education

BDS, MSc, MSPH, MHPE, FFPH, ScD. Associate Prof. of Epidemiology and Biostatistics. Associate Prof. Medical Education Yusuf Al-Gau Gau d BDS, MSc, MSPH, MHPE, FFPH, ScD Associate Prof. of Epidemiology and Biostatistics Associate Prof. Medical Education Jordan University of Science & Technology Alarming high prevalence

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Cardiovascular Complications in Diabetes

Cardiovascular Complications in Diabetes What is all the fuss about? Cardiovascular Complications in Diabetes Dina Shrestha MD Consultant Endocrinologist Norvic International Hospital and Medical College Hospital for Advanced Medicine and Surgery

More information

Obesita e sindrome metabolica

Obesita e sindrome metabolica Obesita e sindrome metabolica S. Bernasconi Dipartimento età evolutiva Clinica Pediatrica Università di Parma sbernasconi@ao.pr.it Obesita e sindrome metabolica 2500 PUBMED : 2000 Obesity 1500 Ultimo anno

More information

Diabetes in Asian Americans

Diabetes in Asian Americans Diabetes in Asian Americans www.screenat23.org Winston F. Wong, MD National Council of Asian Pacific Islander Physicians www.ncapip.org American Diabetes Association Joslin Diabetes Center National Council

More information

Diabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?

Diabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes? Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double

More information

METABOLIC SYNDROME IN A JORDANIAN COHORT: DEMOGRAPHY, COMPLICATIONS AND PREDICTORS OF CARDIOVASCULAR DISEASES

METABOLIC SYNDROME IN A JORDANIAN COHORT: DEMOGRAPHY, COMPLICATIONS AND PREDICTORS OF CARDIOVASCULAR DISEASES METABOLIC SYNDROME IN A JORDANIAN COHORT: DEMOGRAPHY, COMPLICATIONS AND PREDICTORS OF CARDIOVASCULAR DISEASES Shaher Mahafza MD*, Nawaf Khazaalah MD**, Abdelrazzaq Wraikat MD^, Zuhair Shawagheh MD^, Ahmad

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

The National Diabetes Prevention Program in Washington State March 2012

The National Diabetes Prevention Program in Washington State March 2012 The National Diabetes Prevention Program in Washington State March 2012 Session Objectives 1. Overview of pre-diabetes. 2. Describe the Diabetes Prevention Program (DPP). 3. Eligibility for the DPP. 4.

More information

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,

More information

Metabolic Syndrome. DOPE amines COGS 163

Metabolic Syndrome. DOPE amines COGS 163 Metabolic Syndrome DOPE amines COGS 163 Overview - M etabolic Syndrome - General definition and criteria - Importance of diagnosis - Glucose Homeostasis - Type 2 Diabetes Mellitus - Insulin Resistance

More information

Clinical Recommendations: Patients with Periodontitis

Clinical Recommendations: Patients with Periodontitis The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;

More information